JCyte signs ex-US licensing deal with Santen for retinal disease therapy
JCyte has signed an ex-US licensing deal with Japanese ophthalmic company Santen Pharmaceutical worth up to $252m to develop and commercialise its investigational jCell therapy for a rare genetic eye disorder called retinitis pigmentosa.